Overview
Deallus provides consulting services for the life sciences and healthcare sectors. It helps pharmaceutical, biotechnology, medical device, and healthcare companies with research-driven strategic support, including competitive intelligence, market analyses, pipeline and product strategy, and due diligence for mergers, partnerships, or investments. Its offerings translate scientific and market data into actionable insights through customized reports, dashboards, and advisory services. What sets Deallus apart is its focus on life sciences and health care, combining deep scientific understanding with intelligence and strategy work to deliver targeted, decision-ready analysis. The company aims to help clients make informed, faster decisions to maximize value in drug development, commercialization, and healthcare products.
Work here?Claim your company
Simplify's Take
What believers are saying
- March 2026 hiring added clinical development, forecasting, and oncology capability.
- April 2026 Pharma CI Europe positioning signals strong demand for hybrid intelligence.
- GlobalData’s 2026 AI-first transformation increases Deallus’s delivery speed and client reach.
What critics are saying
- GlobalData integration can drain senior talent; losing consultants destroys Deallus’s moat in 2026.
- Premium CI pricing faces pressure as pharma buyers switch to cheaper data platforms.
- If GlobalData centralizes Deallus, the brand becomes a commoditized analytics appendage by 2027.
What makes Deallus unique
- Deallus built 20 years of life-sciences competitive intelligence, strongest in oncology and vaccines.
- GlobalData’s 2024 acquisition gave Deallus proprietary data, AI tools, and broader distribution.
- Its six-office footprint and top-25 pharma client base create rare global coverage.
Help us improve and share your feedback! Did you find this helpful?